

Monoclonal antibody COVID-19 infusion Sotrovimab no longer payable in Michigan

Per the U.S. Food & Drug Administration, Sotrovimab is no longer authorized for use in Michigan, effective March 30, 2022. As a result, claims for procedure codes Q0247, M0247 and M0248 are no longer payable for dates of service on or after March 30, 2022. These claims will reject as provider liable.

This change affects Blue Cross commercial, Medicare Plus BlueSM, BCN commercial and BCN AdvantageSM members.

In addition, the FDA announced on April 5, 2022, that Sotrovimab is no longer authorized for use in any U.S. region.

For more information, see the [FDA updates Sotrovimab emergency use authorization](#)* page of the FDA website.

*Clicking this link means that you're leaving the Blue Cross Blue Shield of Michigan and Blue Care Network website. While we recommend this site, we're not responsible for its content.